Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

A Phase 1b/2 study of XMT-1536 in solid tumors

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Disease Types: Solid Tumors

Available at: Roanoke

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

For more information:

https://clinicaltrials.gov/ct2/show/NCT04396340?term=XMT-1536&draw=2&rank=3